Skip to Main Content

Advertisement

Skip Nav Destination

Issue Archive

Table of Contents

Inside Blood

MYELOID NEOPLASIA

In this issue of Blood, Kreutzman and colleagues describe the existence of clonal cytotoxic T and NK cells in over 80% (15 of 18) of patients with CML at diagnosis which persisted during treatment with the tyrosine kinase inhibitors, imatinib and dasatinib.1  Furthermore, they discovered that this clonal lymphocytosis expands further after therapy with dasatinib but not imatinib.

CLINICAL TRIALS

In this issue of Blood, Richardson et al report on a landmark treatment regimen for newly diagnosed myeloma patients that for the first time combines lenalidomide and bortezomib. This effort required a team approach comprising 2 competing pharmaceutical companies (joining forces to study this promising regimen) and multiple academic medical centers.1 

CLINICAL TRIALS

Warfarin and other vitamin K antagonists are very effective for the treatment and prevention of both arterial and venous thromboembolism. Recombinant factor VIIa may not be as effective as previously thought for the urgent reversal of warfarin.

THROMBOSIS & HEMOSTASIS

In this issue of Blood, Pawlinski and colleagues identify myeloid cells and an unidentified nonhematopoietic cell(s) as the source of TF responsible for intravascular coagulation in a mouse model of endotoxemia, excluding a role for EC, VSMC, and platelet cell TF expression.1 

Blood Work

Plenary Paper

PLENARY PAPER

Perspectives

Clinical Trials and Observations

Hematopoiesis and Stem Cells

Immunobiology

Lymphoid Neoplasia

Myeloid Neoplasia

Platelets and Thrombopoiesis

Thrombosis and Hemostasis

Transplantation

Vascular Biology

Correspondence

Errata

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X